Oxford Biomedica PLC Director Dealings / Market Share Purchase (6411C)
January 23 2018 - 4:30AM
UK Regulatory
TIDMOXB
RNS Number : 6411C
Oxford Biomedica PLC
23 January 2018
Director Dealings / Market Share Purchase
Oxford, UK - 23 January 2018: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the
Group, on Monday 22 January 2017 acquired ordinary shares in the
Group as set out below under the market share purchase agreement
outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr
Tallarigo's fees as Chairman, after tax, are to be used to purchase
shares in Oxford BioMedica PLC on a monthly basis at the prevailing
market price.
Interest after
purchase
----------- --------- ---------- ---------------- ----------------------------
Director Title Price Number of Number % of total
/ PDMR per share Ordinary Shares of Ordinary issued
(p) acquired Shares share capital
----------- --------- ---------- ---------------- ------------ --------------
Dr Lorenzo
Tallarigo Chairman 11.1p 23,941 2,197,028 0.07%
----------- --------- ---------- ---------------- ------------ --------------
The issued share capital of the Group is 3,107,704,224 ordinary
1p shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, Orchard
Therapeutics and Immune Design, through which it has long-term
economic interests in other potential gene and cell therapy
products. Oxford BioMedica is based across several locations in
Oxfordshire, UK and employs more than 300 people. Further
information is available at www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUOUKRWKAAURR
(END) Dow Jones Newswires
January 23, 2018 04:30 ET (09:30 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Sep 2023 to Sep 2024